CN104010656B - 使用免疫球蛋白和c1-抑制剂的联合疗法 - Google Patents

使用免疫球蛋白和c1-抑制剂的联合疗法 Download PDF

Info

Publication number
CN104010656B
CN104010656B CN201280046349.8A CN201280046349A CN104010656B CN 104010656 B CN104010656 B CN 104010656B CN 201280046349 A CN201280046349 A CN 201280046349A CN 104010656 B CN104010656 B CN 104010656B
Authority
CN
China
Prior art keywords
inh
immunoglobulin
administered
ivig
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280046349.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104010656A (zh
Inventor
M·巴斯塔
陈新志
M·马特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Original Assignee
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland, US Department of Health and Human Services filed Critical CSL Behring GmbH Deutschland
Publication of CN104010656A publication Critical patent/CN104010656A/zh
Application granted granted Critical
Publication of CN104010656B publication Critical patent/CN104010656B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280046349.8A 2011-09-24 2012-09-21 使用免疫球蛋白和c1-抑制剂的联合疗法 Active CN104010656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
US61/538,832 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (2)

Publication Number Publication Date
CN104010656A CN104010656A (zh) 2014-08-27
CN104010656B true CN104010656B (zh) 2016-02-24

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280046349.8A Active CN104010656B (zh) 2011-09-24 2012-09-21 使用免疫球蛋白和c1-抑制剂的联合疗法

Country Status (10)

Country Link
US (1) US10471142B2 (enExample)
EP (1) EP2758076B1 (enExample)
JP (1) JP6190368B2 (enExample)
KR (1) KR101956585B1 (enExample)
CN (1) CN104010656B (enExample)
AU (1) AU2012311483B2 (enExample)
CA (1) CA2848510A1 (enExample)
DK (1) DK2758076T3 (enExample)
ES (1) ES2714999T3 (enExample)
WO (1) WO2013041677A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
WO2014131865A1 (en) * 2013-02-28 2014-09-04 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
SI2968434T1 (sl) 2013-03-15 2017-11-30 Shire Viropharma Incorporated, C1-INH sestavki za uporabo pri preprečevanju in zdravljenju hereditarnega angioedema (HAE)
AU2014262890B2 (en) * 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
HUE041809T2 (hu) * 2013-11-22 2019-05-28 Shire Viropharma Inc Eljárások antitest által közvetített kilökõdés kezelésére szervbeültetéses páciensekben C1-észteráz inhibitorral
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
MX2017010323A (es) * 2015-02-20 2017-12-07 Csl Behring Gmbh Formulaciones farmaceuticas de inhibidor de esterasa c1.
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750844A (zh) * 2003-02-21 2006-03-22 唐纳士公司 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
HRP20110622T1 (hr) 2005-12-21 2011-09-30 Pharming Intellectual Property B.V. Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
BRPI1012082B1 (pt) 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750844A (zh) * 2003-02-21 2006-03-22 唐纳士公司 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuroprotection in Stroke by Complement Inhibition and Immunoglobulin Therapy;Thiruma V. Arumugama et al.;《Neuroscience》;20090206;第158卷(第3期);1074-1089 *

Also Published As

Publication number Publication date
KR101956585B1 (ko) 2019-03-11
KR20140075753A (ko) 2014-06-19
JP2014526541A (ja) 2014-10-06
AU2012311483A1 (en) 2013-05-16
EP2758076B1 (en) 2018-12-12
HK1200334A1 (en) 2015-08-07
US20140234293A1 (en) 2014-08-21
US10471142B2 (en) 2019-11-12
ES2714999T3 (es) 2019-05-31
AU2012311483B2 (en) 2016-03-10
EP2758076A1 (en) 2014-07-30
CN104010656A (zh) 2014-08-27
DK2758076T3 (en) 2019-04-01
WO2013041677A1 (en) 2013-03-28
CA2848510A1 (en) 2013-03-28
JP6190368B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
CN104010656B (zh) 使用免疫球蛋白和c1-抑制剂的联合疗法
JP7080263B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤
TWI831106B (zh) 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
Ishrat et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats
WO2012174055A1 (en) Wound healing using complement inhibitors
BR112015006189A2 (pt) anticorpo anti-gm-csf, composição farmacêutica, e, uso de um anticorpo anti-gm-csf na fabricação de um medicamento
Xiaohong et al. CFLAR is a critical regulator of cerebral ischaemia-reperfusion injury through regulating inflammation and endoplasmic reticulum (ER) stress
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
NZ719724A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
Chen et al. Combination therapy with low-dose IVIG and a C1-esterase inhibitor ameliorates brain damage and functional deficits in experimental ischemic stroke
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
US20240358721A1 (en) Gasdermin-d inhibitors and uses thereof for treating pulmonary vaso-occlusion
JP2022125248A (ja) 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
KR20200052310A (ko) 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물
EA013008B1 (ru) Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с
CN104869994B (zh) 匹多莫德治疗银屑病的用途
WO2023222051A1 (zh) Mif和ripk1在围术期缺血性脑损伤中的应用
JP7246094B2 (ja) 活性調節剤
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor
KR20240025512A (ko) 건선의 치료 방법
US20200062855A1 (en) Compositions and methods of promoting wound healing
WO2025036347A1 (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
TW201817426A (zh) 三萜混合物用以治療多發性硬化的用途
ITTO20090515A1 (it) Composizione per il trattamento di infertilita' maschile
HK1230094A1 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant